NCT01937468
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 27 versions: 17 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 31 words Show 5 more changesShow less
- Study completion pushed from Dec 2026 to Dec 2027
- Secondary endpoints: details revised at 1 of 3 entries
- Site details revised at 1 of 2 sites
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 2 words
- Minor Study completion date: Dec 2025 to Dec 2026v26
- Minor Study completion date: Dec 2024 to Dec 2025v24
- Minor Collaborators revised (3)v23
- Minor Study completion date: Dec 2023 to Dec 2024v21
Show 11 earlier versionsHide 11 earlier versions
- Minor Study completion date: Dec 2021 to Dec 2023v19
- Minor Study completion date: Dec 2020 to Dec 2021v17
- Minor Collaborators revised (3)v16
- Minor Study completion date: Nov 2020 to Dec 2020
- Collaborators revised (3)
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Nov 2018 to Aug 2017
- Site details revised at 2 of 2 sites
- Notable Primary completion date: Nov 2016 to Nov 2018
- Study completion date: Jul 2018 to Nov 2020
- Notable Eligibility criteria shortened, about 7 wordsv8
- Notable Trial status: Suspended to Recruiting
- Site details revised at 2 of 2 sites
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: IL-2 supply shortage
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria expanded, about 7 wordsv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 2013 to Nov 2013
- Site details revised at 2 of 2 sites
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
Other: Treg-enriched infusion
Drugs: Interleukin-2
Sites
2 sites in 1 country